US focuses pharma supply chain scrutiny


The US Food and Drug Administration (FDA) has named 13 companies that will be allowed to import drug products into the US with reduced scrutiny. Each company will be permitted to import up to five products under expedited entry arrangements for a period of two years.

The FDA’s Secure Supply Chain Pilot Program is an effort to free up the agency’s resources to focus on areas where imports pose the greatest risk to patients and consumers. The scheme rewards manufacturers for voluntarily adopting best practice and integrating integrity and security into their supply chain operations.

The move comes in the wake of a string of product recalls and import bans as some elements of the pharma industry struggle to maintain appropriate quality standards.


Related Content

Reaching out

22 May 2014 Premium contentFeature

news image

Andy Extance surveys how pharma uses outsourcing in a variety of different ways

Business roundup

28 March 2012 Business

news image

Industry news, April 2012

Most Read

Yeast turned into morphine and opioid biofactories

24 August 2014 Research

news image

Scientists hope that biotech route could protect the drug supply chain from harvest failures and problems with illicit use

No-frills coats set a trend for designer viruses

26 August 2014 Research

news image

An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...

Most Commented

UCLA chemist avoids prison time for lethal lab accident

26 June 2014 News and Analysis

news image

Out-of-court agreement resolves ongoing lab safety case

Next Mars rover will make oxygen from CO2

4 August 2014 News and Analysis

news image

Mars 2020 will set Nasa’s space exploration on a self-sufficiency course